Sequential chemo-durvalumab, reduced-dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial) Francesco Agustoni, Jessica Saddi, Diego Luigi Cortinovis, Stefano Arcangeli, Luca Sala, Catherine Klersy, Valeria Musella, Giulia Galli, Sabrina Maria Chiara Borgetto, Giulia Maria Stella, Daniela Cicognini, Alessandra Ferrari, Paolo Pedrazzoli, Francesco Grossi, Andrea Riccardo Filippi Jnci Cancer Spectrum, 2026 Background The PACIFIC study established the standard of care for unresectable, stage III non-small cell lung cancer (NSCLC). The DEDALUS trial is a phase 2, open-label, multicenter study enrolling patients who are eligible for sequential chemo-radiation therapy (CRT) plus immunotherapy. Methods Patients had unresectable stage IIIA-C NSCLC, regardless of PD-L1 status. After 3 cycles of chemo-durvalumab, responders received hypo-fractionated thoracic radiotherapy (45 Gy over 3 weeks) with durvalumab, then continued durvalumab for up to 12 months or until disease progression. Primary endpoint was safety, assessed by the incidence of grade 3 and 4 possibly related adverse events (PRAEs) within 6 months. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and quality of life (NCT05128630). Results Between February 2022 and August 2024, 28 patients were screened, and 25 enrolled across 3 Italian centers. Enrollment was halted early due to low recruitment. We recorded 9 grade 3-4 PRAEs, which accounted for 6.4% of all AEs; 7 patients (28%) experienced at least 1 grade 3-4 PRAE. Only 1 was immune-related, while the remaining PRAEs were related to chemotherapy, none to RT. Median PFS was 13.2 months (95% CI = 4.9 to 18.6), median OS was 17.5 months (95% CI = 10.7 to 18.6). Among the 16 patients who started maintenance without progression median PFS was 18.6 months (95% CI = 12.8 to not reached), median OS was not reached. Conclusions The early closure of the study and the reduced sample size make it difficult to draw significant conclusions. However, feasibility and safety seem to be acceptable, and early PFS and OS data are promising, especially for patients who completed the full treatment sequence.
Thyroid toxicity in lung cancer patients treated with immune-checkpoint inhibitors: a single-center retrospective analysis Niccolò Leandro Alessio, Gabriele Ferrari, Antonio Mastrelia, Virginia Valeria Ferretti, Giulia Gambini, Pietro Carlo Lucotti, Francesca Rifaldi, Irene Lanzetta, Anna Tortorella, Sabrina Borgetto, Giulia Galli, Salvatore Corallo, Paolo Pedrazzoli, Francesco Agustoni Frontiers in Immunology, 2026 Background Lung cancer is the leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have radically changed the treatment of lung cancer gradually entering all treatment settings. Alongside their clinical benefits, ICIs are associated with immune-related adverse events (irAEs), among which endocrine toxicities, particularly thyroid dysfunctions, represent some of the most frequent. Methods We conducted a retrospective analysis of 420 lung cancer patients referred to the oncology unit of IRCCS Policlinico San Matteo in Pavia, between March 2016 and December 2024. Clinical and treatment-related data were reviewed to identify thyroid irAEs. Comparative analyses between patients with and without thyroid dysfunction were performed using descriptive statistics and survival outcomes. Results Among 420 lung cancer patients treated with ICIs, 69 (16.4%) developed thyroid irAEs. Most events occurred in the first 6 months, and the majority were grade 1–2 (G1 31.9%, G2 66.7%, G3 1.4%). Thyroid replacement therapy was required in 65.2%, while steroids were used in 13%. Male sex was associated with a lower incidence of thyroid irAEs (p 0.050), non-small cell lung cancer (NSCLC) not otherwise specified (NOS) histology was associated with a higher risk (p 0.021). Disease stage and treatment line were not significantly correlated. Patients experiencing thyroid irAEs were more likely to achieve an objective response (CR/PR) compared with those without (p 0.028). Moreover, patients with PD as best response showed a significantly lower incidence of thyroid irAEs compared to those with SD (p 0.010). Duration of response was significantly longer in patients with thyroid irAEs (median 34 vs 17 months; p 0.047). Time-dependent Cox models did not demonstrate a significant association between thyroid irAEs and progression-free survival - PFS (HR 1.08, p 0.66) or overall survival – OS (HR 1.02, p 0.89). Conclusions The occurrence of thyroid irAEs correlated with better tumor response rates and prolonged duration of response, while not significantly impacting PFS or OS. These findings support the hypothesis that thyroid irAEs may serve as a favorable immunologic and prognostic biomarker in the context of ICI therapy.
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC A. Cavazzoni, M. Pagano Mariano, A. Palladini, G. Digiacomo, S. La Monica, M. Bonelli, M. Galetti, I. Pace, R. Roncarati, E. Giovannetti, P. Aretini, R. Minari, M. Treccani, M. Pluchino, C.A. Lagrasta, S. Angelicola, G. Mazzaschi, P. Bordi, F. Gelsomino, F. Agustoni, P.G. Petronini, M. Tiseo, M. Ferracin, R. Alfieri Lung Cancer, 2026
Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment Salvatore Corallo, Francesco Agustoni, Anna Pagani, Francesco Serra, Alessandra Ferrari, Nicola Personeni, Paolo Pedrazzoli, Chiara Citterio Clinical Colorectal Cancer, 2026 BACKGROUND: Regorafenib and fruquintinib are key treatment options for later-line therapy in metastatic colorectal cancer. In the absence of direct comparative studies, treatment selection frequently depends on safety profiles. The weighted toxicity score (WTS) was developed to summarize overall toxicity within a single arm of a randomized clinical trial, facilitating toxicity-benefit evaluations. MATERIAL AND METHODS: In this analysis, WTS was applied to the CORRECT and FRESCO-2 trials. Adverse events (AEs) from both studies were analyzed, and toxicity burden was assessed by comparing WTS differences between trial arms. AEs were classified as either measurable or symptomatic, resulting in the calculation of measurable-WTS (M-WTS) and symptomatic-WTS (S-WTS). For a deeper characterization of treatment-attributable toxicities between the drugs, 3 additional metrics were employed: attributable fraction, which quantifies the proportion of each toxicity rate attributable to the study drug, risk difference, and toxicity incidence rate ratio (TIRR), which measures the frequency of each AE adjusted for toxicity likely related to the underlying disease. RESULTS: After adjustment for placebo-related toxicity, fruquintinib and regorafenib increased the toxicity burden by 97.8% and 85.1%, respectively. Regorafenib was associated with a greater increase in symptomatic toxicity, while fruquintinib was linked to a greater increase in measurable toxicities. Comparative TIRR analysis demonstrated that regorafenib was associated with a higher risk of dysphonia, oral mucositis, weight loss, and fever. In contrast, fruquintinib exceeded regorafenib in the risk of hand-foot skin reaction, transaminase elevation, constipation, and hypertension. CONCLUSION: These findings may support clinicians in making more informed treatment decisions by distinguishing between drug-related toxicity and cancer-related effects.
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database Maria Lucia Reale, Daniela Scattolin, Antonio Vitale, Francesco Passiglia, Salvatore Grisanti, Marianna Macerelli, Domenico Galetta, Claudio Sini, Gabriele Minuti, Fabrizio Citarella, Elisa Roca, Francesco Agustoni, Alessandra Dodi, Diego Cortinovis, Lorenzo Belluomini, Serena Ricciardi, Antonello Veccia, Elio Gregory Pizzutilo, Vieri Scotti, Greta Alì, Francesca Mazzoni, Alessandro Russo, Daniele Pignataro, Alessandra Bulotta, Pierluigi Piovano, Concetta Sergi, Anna Bettini, Carlo Genova, Alberto Pavan, Hector José Soto Parra, Cinzia Ortega, Daniele Pozzessere, Tiziana Vavalà, Rita Chiari, Cristina Zannori, Alessandro D’Aveni, Giulia Meoni, Diana Giannarelli, Umberto Malapelle, Silvia Novello, Emilio Bria, Giulia Pasello Lung Cancer, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo, David J Pinato, Giulia La Cava, Jarushka Naidoo, Artur Katz, Monica Loza, Joel W Neal, Carlo Genova, Scott Gettinger, So Yeon Kim, Ritujith Jayakrishnan, Talal El Zarif, Marco Russano, Federica Pecci, Alessandro Di Federico, Joao V Alessi, Michele Montrone, Dwight H Owen, Sara Ramella, Diego Signorelli, Mary Jo Fidler, Mingjia Li, Andrea Camerini, Balazs Halmos, Bruno Vincenzi, Giulio Metro, Francesco Passiglia, Sai Yendamuri, Annalisa Guida, Michele Ghidini, Antonio D’Alessio, Giuseppe L Banna, Claudia A M Fulgenzi, Salvatore Grisanti, Francesco Grossi, Armida D’Incecco, Eleni Josephides, Mieke Van Hemelrijck, Alessandro Russo, Alain Gelibter, Gianpaolo Spinelli, Monica Verrico, Bartłomiej Tomasik, Raffaele Giusti, Kirsty Balachandran, Emilio Bria, Martin Sebastian, Maximilian Rost, Martin Forster, Uma Mukherjee, Lorenza Landi, Francesca Mazzoni, Avinash Aujayeb, Manuel Dupont, Alessandra Curioni-Fontecedro, Rita Chiari, Vincenzo Sforza, Marcello Tiseo, Alex Friedlaender, Alfredo Addeo, Federica Zoratto, Michele De Tursi, Luca Cantini, Elisa Roca, Giannis Mountzios, Danilo Rocco, Luigi Della Gravara, Sukumar Kalvapudi, Alessandro Inno, Paolo Bironzo, Rafael Di Marco Barros, David O’Reilly, Orla Fitzpatrick, Eleni Karapanagiotou, Isabelle Monnet, Javier Baena, Marianna Macerelli, Aida Piedra, Francesco Agustoni, Diego Luigi Cortinovis, Giuseppe Tonini, Gabriele Minuti, Chiara Bennati, Laura Mezquita, Teresa Gorría, Alberto Servetto, Teresa Beninato, Giuseppe Lo Russo, Arsela Prelaj, Andrea De Giglio, Jacobo Rogado, Laura Moliner, Ernest Nadal, Federica Biello, Frank Aboubakar Nana, Anne-Marie Dingemans, Joachim G J V Aerts, Roberto Ferrara, Taher Abu Hejleh, Kazuki Takada, Abdul Rafeh Naqash, Marina Chiara Garassino, Solange Peters, Heather A Wakelee, Amin H Nassar, Biagio Ricciuti, Paolo Soda, Camillo Maria Caruso, Valerio Guarrasi Journal for Immunotherapy of Cancer, 2025 Background With nearly one-third of patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 Tumor Proportion Score≥50% surviving beyond 5 years following first-line pembrolizumab, long-term outcomes challenge traditional paradigms of cancer prognostication. The emergence of non-cancer-related factors and time-dependent trends underscores the need for advanced analytical frameworks to unravel their complex interplay. Methods We analyzed the Pembro-real 5Y registry, a global real-world dataset of 1050 patients treated across 61 institutions in 14 countries with a long-term follow-up and a large panel of baseline variables. Two complementary approaches were employed: ridge regression, chosen for its ability to address multicollinearity while retaining interpretability, and not another imputation method (NAIM), a transformer-based artificial intelligence model designed to handle missing data without imputation. Endpoints included risk of death at 6, 12, 24, 60 months and 5-year survival. Results The ridge regression model achieved a c-statistic of 0.66 (95% CI: 0.59 to 0.72) for the risk of death and an area under the curve (AUC) of 0.72 (95% CI: 0.65 to 0.78) for 5-year survival, identifying Eastern Cooperative Oncology Group Performance Status (ECOG-PS)≥2, increasing age, and metastatic burden as primary risk factors. However, wide CIs for some predictors highlighted statistical instability. NAIM demonstrated robust handling of missing data, with a c-index of 62.98±2.11 for risk of death and an AUC of 60.52±3.71 for 5-year survival. The comprehensive SHapley Additive exPlanations analysis revealed dynamic, time-dependent patterns, with early mortality dominated by acute factors (eg, ECOG-PS, steroids) and long-term outcomes increasingly influenced by systemic health markers (eg, absence of hypertension, increasing body mass index). Unexpected insights included the protective role of dyslipidemia (but not statins) and the nuanced impact of smoking status, reflecting evolving disease dynamics and host-tumor interplay. Conclusions Our integrative framework illuminates the complexity of long-term outcomes in patients with NSCLC treated with pembrolizumab, uncovering dynamic, non-linear prognostication trends. This analysis provides insights into patient trajectories, emphasizing the need for holistic, long-term management strategies.
Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI Gaia Messana, Chandra Bortolotto, Sithin Thulasi Seetha, Alessandra Marrocco, Carlotta Pairazzi, Francesco Sanvito, Francesca Brero, Agnese Robustelli Test, Raffaella Fiamma Cabini, Alessandro Lascialfari, Domenico Zacà, Giulia Maria Stella, Francesco Agustoni, Jessica Saddi, Andrea Riccardo Filippi, Lorenzo Preda European Radiology, 2025 Objectives This study aimed to assess whether pharmacokinetic parameters derived from DCE-MRI can stratify Programmed Death-Ligand 1 (PD-L1) expression in NSCLC. The secondary aim was to identify a suitable pharmacokinetic model configuration for anisotropic temporally-spaced DCE-MRI sequences, considering Tofts variants, population-averaged arterial input functions (AIF), and bolus arrival time (BAT) estimation methods. Materials and methods From April 2021 to May 2023, patients with locally advanced non-small cell lung cancer (NSCLC) were prospectively enrolled. Tumors were categorized based on: PD-L1 absence/presence (threshold 1%) and hyperexpression/hypoexpression (threshold 50%). Pharmacokinetic parameters were extracted using several candidate configurations; fit quality was evaluated using coefficient of determination (R²). Mann–Whitney U-test and ROC-AUC were used to assess correlation with PD-L1 for the best-fit configuration. Results Thirty-eight patients (mean age 68 ± 9 years, 28 men) were included. PD-L1 expression was present in 25 patients (66%) and absent in 13 (34%). PD-L1 was hyperexpressed in 13 (34%) patients and hypoexpressed in 25 (66%). Voxel-wise pharmacokinetic parameters were extracted using the best-fit configuration—extended Tofts model (ETM) with Georgiou AIF and Peak-Gradient (PG) BAT estimation (R 2 = 0.79). Ktrans median (0.25 vs. 0.12 min−¹, p = 0.02), Ktrans standard deviation (0.32 vs. 0.23 min−¹, p = 0.01) and Kep median (1.09 vs. 0.59 min−¹, p = 0.02) were significantly higher in PD-L1 < 50% group (ROC-AUC 0.71–0.76). Conclusion DCE-MRI pharmacokinetic parameters could stratify PD-L1 hypo/hyperexpression in NSCLC. The ETM with PG BAT estimation method and Georgiou AIF was the best-performing pharmacokinetic configuration. Key Points Question Could Dynamic Contrast-Enhanced (DCE) MRI offer a safe and non-invasive way to assess Programmed Death-Ligand 1 (PD-L1) expression? Findings Quantitative DCE-MRI parameters K trans (the volume transfer rate) and Kep (the efflux rate constant) show potential for distinguishing PD-L1 hyperexpression from hypoexpression. Clinical relevance Preliminary results suggest that DCE-MRI could be a safe method to stratify PD-L1 hypo/hyperexpression in non-small cell lung cancer, potentially optimizing treatment decisions, given the high cost of immunotherapy. Graphical Abstract
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study A.R. Filippi, M.R. García Campelo, J.-B. Paoli, D. Kowalski, C. Bennati, P. Borghetti, D. Cortinovis, A. Delmonte, C. Genova, S. Van Hulst, R.M. Mroz, S. Nawrocki, I. Toledano, G. Tonini, F. Agustoni, G. Wetherill, Z. Zhu, I.D. Perez, K. Foroutanpour, N. Georgoulia, R. Dziadziuszko ESMO Open, 2025 BACKGROUND: Currently, patients with unresectable stage III non-small-cell lung cancer (NSCLC) ineligible for chemotherapy receive radiotherapy alone, with unsatisfactory results. DUART was a phase II single-arm trial of durvalumab in patients without progression after radiotherapy for unresectable stage III NSCLC. PATIENTS AND METHODS: Patients were enrolled into parallel cohorts per radiotherapy dose (A: definitive; B: palliative) and received durvalumab (1500 mg every 4 weeks for up to 12 months). The primary endpoint was incidence of grade 3/4 possibly related adverse events (PRAEs) within 6 months of durvalumab initiation. Secondary endpoints included objective response rate, progression-free survival (PFS), and overall survival (OS). Exploratory circulating tumor (ctDNA) analyses utilized a targeted methylation assay (GRAIL, Inc.). RESULTS: As of 06 December 2023, 102 patients received durvalumab (cohort A: 53; cohort B: 49); 18.8%/73.3%/7.9% had Eastern Cooperative Oncology Group performance status 0/1/2 and median age was 79.0 years. Overall, 9.8% [95% confidence interval (CI) 4.8% to 17.3%] had grade 3/4 PRAEs within 6 months of durvalumab initiation. Median PFS (investigator assessed) was 9.2 months, with a 12-month landmark rate of 39.6%. Median OS was 21.1 months and the 12-month landmark rate was 64.7%. Patients who were ctDNA positive at cycle 1 or 7 had shorter PFS versus patients who were ctDNA negative at the same time point. CONCLUSIONS: The safety profile of durvalumab after radiotherapy was consistent with PACIFIC (durvalumab after chemoradiotherapy). Efficacy across cohorts was encouraging. Some patients may achieve or maintain molecular remission with durvalumab even after palliative radiotherapy. Durvalumab following radiotherapy may be a potential treatment option in a frailer, older, chemotherapy-ineligible population.
Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients Daniele Lorenzini, Gabriella Gaudioso, Alessandro Scardoni, Lorenzo Blandi, Alessandro Del Gobbo, Paola Rafaniello Raviele, Stefano Ferrero, Silvio M. Veronese, Calogero Lauricella, Fabio Pagni, Davide Seminati, Monica Miozzo, Chiara Pesenti, Umberto Gianelli, Simona Buiatiotis, Caterina Fumagalli, Elena Guerini Rocco, Alessandra Rappa, Massimo Barberis, Nicola Fusco, Alberto Ranghiero, Stefano La Rosa, Fausto Sessa, Daniela Furlan, Nora Sahnane, Carlo Patriarca, Maria Giulia Cangi, Alessandra Lume, Claudio Doglioni, Maurilio Ponzoni, William Vermi, Mauro Novali, Marco Paulli, Emanuela Boveri, Luigi Terracciano, Silvia Uccella, Annarita Destro, Elena Tamborini, Federica Perrone, Fabio Pasotti, Francesco Agustoni, Filippo De Braud, Francesco Grossi, Salvatore Siena, Giuseppe Curigliano, Sabrina Buoro, Giancarlo Pruneri Tumori, 2025 Background: Recent advancements in identifying druggable molecular drivers in lung adenocarcinoma (LUAD), have transformed treatment paradigms. In recent years, Next Generation Sequencing (NGS) has gained momentum as an essential tool for in-depth simultaneous analysis of multiple genes, thereby streamlining the diagnostic process in LUAD. Despite this, the implementation of NGS testing in both the US and Europe remains suboptimal. Aims: In compliance with a decree issued by the Italian Ministry of Health, Lombardy Region recently launched an initiative to implement NGS testing in patients with advanced LUAD. In this context, a real-world prospective observational study was planned to assess the efficacy of the regional network of molecular laboratories in testing nine biomarkers ( KRAS p.G12C, EGFR , BRAF, HER2, MET mutations; ALK , ROS1 , NTRK1-3 , RET rearrangements), for on-label molecularly targeted drugs. Results: In 2023, out of the 2784 advanced/metastatic LUAD patients expected in Lombardy, 2343 (84.2%) were successfully evaluated with an NGS panel including all the nine biomarkers for on-label drugs. Actionable aberrations were identified in 45.5% of the patients (1068/2343), predominantly involving EGFR , KRAS , and ALK genes. Conclusion: Our data provide evidence that establishing a structured network of NGS hubs is mandatory to ensure access of advanced LUAD patients to molecularly targeted treatments.
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets Francesco Rocco Bertuccio, Simone Montini, Maria Antonietta Fusco, Antonella Di Gennaro, Gaetano Sciandrone, Francesco Agustoni, Giulia Galli, Chandra Bortolotto, Jessica Saddi, Guido Baietto, Giulio Melloni, Gioacchino D’Ambrosio, Angelo Guido Corsico, Giulia Maria Stella Cancers, 2025
Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group Chiara Catania, Claudia Proto, Chiara Bennati, Salvatore Grisanti, Ida Colantonio, Francesco Petrella, Andrea Riccardo Filippi, Carlo Genova, Gaia Piperno, Nazario Teodorani, Carlo Greco, Claudia Sangalli, Vieri Scotti, Francesco Agustoni, Emanuela Olmetto, Marco Russano, Vincenzo Agbaje, Angelo Platania, Marzia Di Pietro Paolo, Paolo Borghetti, Jessica Saddi, Michela Marcenaro, Stefania Martini, Alessandro Russo Critical Reviews in Oncology Hematology, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato, Jarushka Naidoo, Artur Katz, Monica Loza, Joel W Neal, Carlo Genova, Scott Gettinger, So Yeon Kim, Ritujith Jayakrishnan, Talal El Zarif, Marco Russano, Federica Pecci, Alessandro Di Federico, Mark Awad, Joao V Alessi, Michele Montrone, Dwight Hall Owen, Diego Signorelli, Mary Jo Fidler, Mingjia Li, Andrea Camerini, Andrea De Giglio, Lauren Young, Bruno Vincenzi, Giulio Metro, Francesco Passiglia, Sai Yendamuri, Annalisa Guida, Michele Ghidini, Nichola O Awosika, Andrea Napolitano, Claudia A M Fulgenzi, Salvatore Grisanti, Francesco Grossi, Armida D’Incecco, Eleni Josephides, Mieke Van Hemelrijck, Alessandro Russo, Alain Gelibter, Gianpaolo Spinelli, Monica Verrico, Bartłomiej Tomasik, Raffaele Giusti, Thomas Newsom-Davis, Emilio Bria, Martin Sebastian, Maximilian Rost, Martin Forster, Uma Mukherjee, Lorenza Landi, Francesca Mazzoni, Avinash Aujayeb, Manuel Dupont, Alessandra Curioni-Fontecedro, Rita Chiari, Francesco Pantano, Alessandro Morabito, Alessandro Leonetti, Alex Friedlaender, Alfredo Addeo, Federica Zoratto, Michele De Tursi, Luca Cantini, Elisa Roca, Giannis Mountzios, Luigi Della Gravara, Sukumar Kalvapudi, Alessandro Inno, Paolo Bironzo, Rafael Di Marco Barros, David O’Reilly, Jack Bell, Eleni Karapanagiotou, Isabelle Monnet, Javier Baena, Marianna Macerelli, Margarita Majem, Francesco Agustoni, Diego Luigi Cortinovis, Giuseppe Tonini, Gabriele Minuti, Chiara Bennati, Laura Mezquita, Teresa Gorría, Alberto Servetto, Teresa Beninato, Giuseppe Lo Russo, Jacobo Rogado, Laura Moliner, Federica Biello, Frank Aboubakar Nana, Anne-Marie Dingemans, Joachim G J V Aerts, Roberto Ferrara, Valter Torri, Taher Abu Hejleh, Kazuki Takada, Abdul Rafeh Naqash, Marina Garassino, Solange Peters, Heather Wakelee, Amin H Nassar, Biagio Ricciuti Journal for Immunotherapy of Cancer, 2025
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach Giovanni Luca Ceresoli, Giulio Rossi, Francesco Agustoni, Lucia Bonomi, Paolo Borghetti, Alessandra Bulotta, Clelia Casartelli, Giulio Cerea, Francesca Colonese, Ester del Signore, Giovanna Finocchiaro, Letizia Gianoncelli, Salvatore Grisanti, Martina Maiolani, Fabio Pagni, Claudia Proto, Erika Rijavec, Isabella Vittimberga, Stefano Arcangeli, Andrea Riccardo Filippi Critical Reviews in Oncology Hematology, 2024
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium M.V. Lenti, D.G. Ribaldone, F. Borrelli de Andreis, M. Vernero, B. Barberio, M. De Ruvo, E.V. Savarino, T. Kav, A. Blesl, M. Franzoi, H.P. Gröchenig, D. Pugliese, G. Ianiro, S. Porcari, G. Cammarota, A. Gasbarrini, R. Spagnuolo, P. Ellul, K. Foteinogiannopoulou, I. Koutroubakis, K. Argyriou, M. Cappello, A. Jauregui-Amezaga, M.G. Demarzo, N. Silvestris, A. Armuzzi, F. Sottotetti, L. Bertani, S. Festa, P. Eder, P. Pedrazzoli, A. Lasagna, A. Vanoli, G. Gambini, G. Santacroce, C.M. Rossi, M. Delliponti, C. Klersy, G.R. Corazza, A. Di Sabatino, C. Mengoli, N. Aronico, F. Lepore, G. Broglio, S. Merli, G. Natalello, E. Alimenti, D. Scalvini, S. Muscarella, F. Agustoni, A. Pagani, S. Chiellino, S. Corallo, V. Musella, R. Cannizzaro, M. Vecchi, F. Caprioli, R. Gabbiadini, A. Dal Buono, A. Premoli, L.D. Locati, A. Buda, A. Contaldo, A. Schiepatti, F. Biagi, D. Morano, M. Cucè, A. Kotsakis, G. De Lisi ESMO Open, 2024
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research Arsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, Laura Mazzeo, Giuseppe Viscardi, Giulio Metro, Giulia Galli, Francesco Agustoni, Carminia Maria Della Corte, Andrea Spagnoletti, Claudia Giani, Roberto Ferrara, Claudia Proto, Marta Brambilla, Andra Diana Dumitrascu, Alessandro Inno, Diego Signorelli, Elio Gregory Pizzutilo, Matteo Brighenti, Federica Biello, Chiara Bennati, Luca Toschi, Marco Russano, Alessio Cortellini, Chiara Catania, Federica Bertolini, Rossana Berardi, Luca Cantini, Federica Pecci, Marianna Macerelli, Rita Emili, Claudia Bareggi, Francesco Verderame, Antonio Lugini, Salvatore Pisconti, Federica Buzzacchino, Michele Aieta, Alfredo Tartarone, Gianpaolo Spinelli, Emanuele Vita, Salvatore Grisanti, Francesco Trovò, Pietro Auletta, Daniele Lorenzini, Luca Agnelli, Sabina Sangaletti, Francesca Mazzoni, Giuseppina Calareso, Margherita Ruggirello, Gabriella Francesca Greco, Raffaella Vigorito, Mario Occhipinti, Sara Manglaviti, Teresa Beninato, Rita Leporati, Paolo Ambrosini, Roberta Serino, Cecilia Silvestri, Emanuela Zito, Alessandra Chiara Laura Pedrocchi, Vanja Miskovic, Filippo de Braud, Giancarlo Pruneri, Giuseppe Lo Russo, Carlo Genova, Andrea Vingiani Clinical Lung Cancer, 2024
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program Francesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, Giulia Pasello, Gabriele Minuti, Alessandra Bulotta, Domenico Galetta, Giacomo Pelizzari, Claudio Sini, Emilio Bria, Elisa Roca, Sara Pilotto, Carlo Genova, Giulio Metro, Fabrizio Citarella, Rita Chiari, Diego Cortinovis, Angelo Delmonte, Alessandro Russo, Marcello Tiseo, Giulio Cerea, Annamaria Carta, Vieri Scotti, Tiziana Vavalà, Marta Brambilla, Lucio Buffoni, Roberta Buosi, Chiara Catania, Stefania Gori, Salvatore Grisanti, Francesco Agustoni, Edoardo Garbo, Umberto Malapelle, Silvia Novello Lung Cancer, 2024
Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease Francesco Rocco Bertuccio, Francesco Agustoni, Giulia Galli, Chandra Bortolotto, Jessica Saddi, Guido Baietto, Nicola Baio, Simone Montini, Paola Putignano, Gioacchino D’Ambrosio, Angelo G. Corsico, Paolo Pedrazzoli, Giulia Maria Stella Cancers, 2023
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) Stefano Cavalieri, Viviana Vitolo, Amelia Barcellini, Sara Ronchi, Angelica Facoetti, Chiara Campo, Catherine Klersy, Silvia Molinelli, Francesco Agustoni, Virginia Valeria Ferretti, Annalisa De Silvestri, Marco Platania, Michele Del Vecchio, Marco Durante, Alexander Helm, Claudia Fournier, Filippo de Braud, Paolo Pedrazzoli, Ester Orlandi, Lisa Licitra Future Oncology, 2023
Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer Gennaro Ciliberto, Marco Canfora, Irene Terrenato, Chiara Agnoletto, Francesco Agustoni, Loredana Amoroso, Gustavo Baldassarre, Giuseppe Curigliano, Angelo Delmonte, Antonella De Luca, Michelangelo Fiorentino, Vanesa Gregorc, Toni Ibrahim, Chiara Lazzari, Angela Mastronuzzi, Paolo Pronzato, Armando Santoro, Giovanni Scambia, Stefania Tommasi, Andrea Vingiani, Patrizio Giacomini, Ruggero De Maria Journal of Experimental and Clinical Cancer Research, 2022
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry Jennifer G. Whisenant, Javier Baena, Alessio Cortellini, Li-Ching Huang, Giuseppe Lo Russo, Luca Porcu, Selina K. Wong, Christine M. Bestvina, Matthew D. Hellmann, Elisa Roca, Hira Rizvi, Isabelle Monnet, Amel Boudjemaa, Jacobo Rogado, Giulia Pasello, Natasha B. Leighl, Oscar Arrieta, Avinash Aujayeb, Ullas Batra, Ahmed Y. Azzam, Mojca Unk, Mohammed A. Azab, Ardak N. Zhumagaliyeva, Carlos Gomez-Martin, Juan B. Blaquier, Erica Geraedts, Giannis Mountzios, Gloria Serrano-Montero, Niels Reinmuth, Linda Coate, Melina Marmarelis, Carolyn J. Presley, Fred R. Hirsch, Pilar Garrido, Hina Khan, Alice Baggi, Celine Mascaux, Balazs Halmos, Giovanni L. Ceresoli, Mary J. Fidler, Vieri Scotti, Anne-Cécile Métivier, Lionel Falchero, Enriqueta Felip, Carlo Genova, Julien Mazieres, Umit Tapan, Julie Brahmer, Emilio Bria, Sonam Puri, Sanjay Popat, Karen L. Reckamp, Floriana Morgillo, Ernest Nadal, Francesca Mazzoni, Francesco Agustoni, Jair Bar, Federica Grosso, Virginie Avrillon, Jyoti D. Patel, Fabio Gomes, Ehab Ibrahim, Annalisa Trama, Anna C. Bettini, Fabrice Barlesi, Anne-Marie Dingemans, Heather Wakelee, Solange Peters, Leora Horn, Marina Chiara Garassino, Valter Torri Journal of Thoracic Oncology, 2022
Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study Laura Saracino, Chandra Bortolotto, Stefano Tomaselli, Elia Fraolini, Matteo Bosio, Giulia Accordino, Francesco Agustoni, David M. Abbott, Emma Pozzi, Dimitrios Eleftheriou, Patrizia Morbini, Pietro Rinaldi, Cristiano Primiceri, Andrea Lancia, Patrizia Comoli, Andrea R. Filippi, Giulia M. Stella BMC Cancer, 2021
Baseline characteristics and outcomes of cancer patients infected with sars-cov-2 in the lombardy region, italy (Aiom-l corona): A multicenter, observational, ambispective, cohort study Serena Di Cosimo, Barbara Tagliaferri, Daniele Generali, Fabiola Giudici, Francesco Agustoni, Antonio Bernardo, Karen Borgonovo, Gabriella Farina, Giovanna Luchena, Andrea Luciani, Franco Nolè, Laura Palmeri, Filippo Pietrantonio, Guido Poggi, Paolo Andrea Zucali, Emanuela Balletti, Giovanna Catania, Ottavia Bernocchi, Federica D’Antonio, Monica Giordano, Francesco Grossi, Angioletta Lasagna, Nicla La Verde, Mariangela Manzoni, Benedetta Montagna, Angelo Olgiati, Alessandra Raimondi, Irene Rampinelli, Elena Verri, Alberto Zaniboni, Massimo Di Maio, Giordano Beretta, Marco Danova Cancers, 2021
THE RESILIENCE OF ONCOLOGISTS DURING THE EARLY TIME OF THE COVID-19 PANDEMIC A. Lasagna, S. Secondino, F. Agustoni, T. Monaco, I. Imarisio, A. Pagani, G. Rizzo, R. J. Tancredi, E. Pozzi, E. Ferraris, S. Chiellino, C. Gandini, A. Ferrari, S. G. Brugnatelli, P. Pedrazzoli Annals of Research in Oncology, 2021
Radiomics features as predictive and prognostic biomarkers in NSCLC Chandra Bortolotto, Andrea Lancia, Chiara Stelitano, Marianna Montesano, Elisa Merizzoli, Francesco Agustoni, Giulia Stella, Lorenzo Preda, Andrea Riccardo Filippi Expert Review of Anticancer Therapy, 2021
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Marina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, Annalisa Trama, Valter Torri, Francesco Agustoni, Javier Baena, Giuseppe Banna, Rossana Berardi, Anna Cecilia Bettini, Emilio Bria, Matteo Brighenti, Jacques Cadranel, Alessandro De Toma, Claudio Chini, Alessio Cortellini, Enriqueta Felip, Giovanna Finocchiaro, Pilar Garrido, Carlo Genova, Raffaele Giusti, Vanesa Gregorc, Francesco Grossi, Federica Grosso, Salvatore Intagliata, Nicla La Verde, Stephen V Liu, Julien Mazieres, Edoardo Mercadante, Olivier Michielin, Gabriele Minuti, Denis Moro-Sibilot, Giulia Pasello, Antonio Passaro, Vieri Scotti, Piergiorgio Solli, Elisa Stroppa, Marcello Tiseo, Giuseppe Viscardi, Luca Voltolini, Yi-Long Wu, Silvia Zai, Vera Pancaldi, Anne-Marie Dingemans, Jan Van Meerbeeck, Fabrice Barlesi, Heather Wakelee, Solange Peters, Leora Horn Lancet Oncology, 2020
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines Shengxiang Ren, Christopher J. Rivard, Hui Yu, Carlo Genova, Leslie Rozenboom, Dexiang Gao, Trista K. Hinz, Brad A. Rikke, Murry W. Wynes, Charles Caldwell, Francesco Agustoni, Kenichi suda, Tao Jiang, Caicun Zhou, Lynn E. Heasley, Fred R. Hirsch Clinical Lung Cancer, 2018
